A. Barrios

发表

Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine

B. Clotet, E. Negredo, V. Soriano, 2005, AIDS.

Gynecomastia in HIV-infected patients receiving antiretroviral therapy.

V. Soriano, J. González-lahoz, F. Blanco, 2003, AIDS research and human retroviruses.

Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir.

V. Soriano, J. González-lahoz, S. Rodríguez-Nóvoa, 2006, AIDS research and human retroviruses.

Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/μl or less

D. Podzamczer, E. Ribera, E. Ferrer, 2004, AIDS.

Simplification Therapy with Once-Daily Didanosine, Tenofovir and Efavirenz in HIV-1-Infected Adults with Viral Suppression Receiving a More Complex Antiretroviral Regimen: Final Results of the EFADITE Trial

B. Clotet, E. Negredo, V. Soriano, 2005, Antiviral therapy.

Estimated extent of cross-resistance to ritonavir-boosted protease inhibitors among protease inhibitors-experienced patients: implications for tipranavir use.

V. Soriano, C. de Mendoza, A. Corral, 2005, AIDS patient care and STDs.

Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma

D. Podzamczer, G. Sirera, J. González-lahoz, 2004, AIDS.

Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia.

J. J. de la Cruz, V. Soriano, J. González-lahoz, 2002, AIDS.

Lipodystrophy body-shape changes in a patient undergoing zidovudine monotherapy.

V. Soriano, J. González-lahoz, F. Blanco, 2002, AIDS.

Tenofovir-related nephrotoxicity in HIV-infected patients.

V. Soriano, J. González-lahoz, A. Barrios, 2004, AIDS.

SENC (Spanish efavirenz vs. nevirapine comparison) trial: A randomized, open-label study in HIV-infected naive individuals

Marina Núñez, Pablo Barreiro, V. Soriano, 2002, HIV clinical trials.

Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1.

V. Soriano, A. Corral, J. González-lahoz, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Predictors of Virological Response to Atazanavir in Protease Inhibitor-Experienced Patients

V. Soriano, J. González-lahoz, I. Jiménez-Nácher, 2004, HIV clinical trials.

A Tool to Distinguish Viral From Bacterial Pneumonia

J. Galán, P. Rojo, J. Jensen, 2021, medRxiv.

Role of Baseline Human Immunodeficiency Virus Genotype as a Predictor of Viral Response to Tenofovir in Heavily Pretreated Patients

V. Soriano, C. de Mendoza, P. Domingo, 2003, Journal of Clinical Microbiology.